2023
A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM).
Davar D, Ikeguchi A, Buchbinder E, Shoushtari A, Seedor R, Bernicker E, Weiss S, Daniels G, Panella T, Ryan H, Goodall H, Sullivan R. A phase 2/3 trial in progress on tebentafusp as monotherapy and in combination with pembrolizumab in HLA-A*02:01+ patients with previously treated advanced non-uveal melanoma (TEBE-AM). Journal Of Clinical Oncology 2023, 41: tps9594-tps9594. DOI: 10.1200/jco.2023.41.16_suppl.tps9594.Peer-Reviewed Original ResearchMetastatic cutaneous melanomaMetastatic uveal melanomaAdvanced melanomaInvestigator's choicePrimary endpointDual primary endpointsOverall survival benefitPhase 3 trialSimilar patient populationsPhase 2/3 trialIC armOS benefitPrior ipilimumabRECIST responseInhibitor regimenSupportive careSurvival benefitCare therapyAnti-CTLA4CtDNA levelsTumor burdenInvestigational agentsPatient populationCutaneous melanomaClinical trials
2020
Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases
Weiss SA, Zito C, Tran T, Heishima K, Neumeister V, McGuire J, Adeniran A, Kluger H, Jilaveanu LB. Melanoma brain metastases have lower T-cell content and microvessel density compared to matched extracranial metastases. Journal Of Neuro-Oncology 2020, 152: 15-25. PMID: 32974852, PMCID: PMC7910371, DOI: 10.1007/s11060-020-03619-0.Peer-Reviewed Original ResearchConceptsT-cell contentMelanoma brain metastasesPD-L1 expressionLower microvessel densityMicrovessel densityBrain metastasesExtracranial metastasesMacrophage contentB cellsProspective therapeutic clinical trialsTumor-infiltrating T cellsImmune-modulating drugsImmune cell subsetsTherapeutic clinical trialsExtracerebral metastasesHigh CD68Low CD3Low CD8Systemic therapyIntracerebral metastasesMetastatic sitesCell subsetsMetastatic melanomaImmune cellsClinical trialsSystemic Therapy for Brain Metastases: Melanoma
Weiss S, Kluger H. Systemic Therapy for Brain Metastases: Melanoma. 2020, 235-244. DOI: 10.1007/978-3-030-42958-4_16.Peer-Reviewed Original ResearchMelanoma brain metastasesIntracranial response ratesBrain metastasesClinical trialsResponse rateAnti-PD-1 monotherapyCentral nervous system metastasesExtracranial metastatic sitesNervous system metastasesSystemic therapy approachesMultiple clinical trialsSystemic therapySystemic treatmentAdvanced melanomaImmune checkpointsMetastatic sitesTherapeutic challengePatient survivalMetastatic melanomaExtracranial sitesStereotactic radiosurgeryMetastasisMutant BRAFSignificant causeMEK inhibition
2019
Immunotherapy of Melanoma: Facts and Hopes
Weiss SA, Wolchok JD, Sznol M. Immunotherapy of Melanoma: Facts and Hopes. Clinical Cancer Research 2019, 25: 5191-5201. PMID: 30923036, PMCID: PMC6726509, DOI: 10.1158/1078-0432.ccr-18-1550.Peer-Reviewed Original ResearchConceptsOverall survivalMetastatic diseaseImmune therapyPredictive biomarkersNivolumab/ipilimumab combinationRandomized phase III trialLong-term clinical benefitImmunobiology of tumorsDuration of therapyPhase III trialsLong-term survivorsEffective immune therapyAdjuvant settingIpilimumab combinationMetastatic settingIII trialsPatient subsetsClinical benefitImmune modulationMetastatic melanomaClinical trialsSingle agentTherapyTrue increaseCell therapy
2017
Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature
Utter K, Goldman C, Weiss SA, Shapiro RL, Berman RS, Wilson MA, Pavlick AC, Osman I. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature. Oncology 2017, 93: 249-258. PMID: 28746931, PMCID: PMC5617794, DOI: 10.1159/000478050.Peer-Reviewed Original ResearchConceptsMUP patientsProspective melanoma databaseSystemic therapyUnknown primaryMetastatic melanomaClinical trialsSingle-institution studyMKP patientsTreatment guidelinesPoor outcomeMelanoma databaseWorse outcomesTreatment outcomesPatientsBetter outcomesTherapyPatient dataMelanomaGoogle ScholarUnique populationSurvival dataOutcomesLimited dataImmunotherapyTrialsTargeting EZH2 in acral lentiginous melanoma (ALM).
Izsak A, Giles K, Lui K, Weiss S, Moran U, Vega-Saenz de Miera E, Stein J, Lee A, Darvishian F, Shapiro R, Berman R, Pavlick A, Wilson M, Osman I. Targeting EZH2 in acral lentiginous melanoma (ALM). Journal Of Clinical Oncology 2017, 35: 9534-9534. DOI: 10.1200/jco.2017.35.15_suppl.9534.Peer-Reviewed Original ResearchAcral lentiginous melanomaCM cell linesCutaneous melanomaALM casesCell linesMetastatic progressionEZH2 expressionMetastatic acral lentiginous melanomaEZH2 inhibitionEZH2 inhibitorsEffects of GSK126Mean IHC scoreColony formationEZH2 protein expressionClinicopathological dataPrimary tumorLentiginous melanomaMetastatic tumorsClinical trialsHistone methyltransferase EZH2Treatment outcomesIHC scoreLow dosesTherapeutic potentialTumors
2014
Update on Vaccines for High-Risk Melanoma
Weiss SA, Chandra S, Pavlick AC. Update on Vaccines for High-Risk Melanoma. Current Treatment Options In Oncology 2014, 15: 269-280. PMID: 24788575, DOI: 10.1007/s11864-014-0283-7.Peer-Reviewed Original ResearchConceptsHigh-risk melanomaRole of vaccinesClinical trialsCytotoxic T-lymphocyte antigen-4Death-1 monoclonal antibodyT-lymphocyte antigen-4Cell death-1 monoclonal antibodyImmunogenic solid tumorsOpinion statementThe managementPrimary surgical resectionHigh-risk diseaseMeaningful clinical responsesGranulocyte-macrophage colony-stimulating factorImmune stimulatory agentsDevelopment of vaccinesMacrophage colony-stimulating factorColony-stimulating factorAdjuvant settingImmunomodulatory therapyAdjuvant optionClinical responseMelanoma vaccineSurgical resectionVaccine therapyClinical outcomes